South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...
Fierce Biotech

Sanofi signs $1B biobucks pact for Alzheimer's asset in 2nd biotech deal of the day

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. | Sanofi is back with its ...
Chosunbiz

Adel licenses ADEL‑Y01 to Sanofi for $1.04B Alzheimer's program

Adel licenses ADEL‑Y01 to Sanofi for $1.04B Alzheimers program Adel signs $1.04 billion technology transfer with Sanofi for ...
PharmExec

Sanofi Reaches Deals with ADEL for Novel Alzheimer’s Disease Drug, Dren Bio for B-cell Depletion Therapy

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Adel clinches $1b Alzheimer’s therapy license deal with Sanofi

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion ...

ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's ...
Contract Pharma

ADEL Enters Global License Agreement with Sanofi for ADEL-Y01

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...